ENTREMED BEGINS PANZEM TRIAL

EntreMed has begun a Phase II clinical trial to evaluate the safety and efficacy drug candidate, Panzem NCD, in combination with Avastin in patients with locally advanced or metastatic carcinoid tumors.

Panzem is an orally active small molecule that attacks tumor cells through multiple mechanisms of action and has antiangiogenic activity. Panzem NCD, a liquid nanocrystal formulation of 2ME2, can attack tumors on multiple fronts -- directly by disrupting microtubules, an intracellular matrix necessary for the rapid division of cancer cells (mitosis), by inducing programmed cell death (apoptosis), and by blocking blood vessels that feed tumors (angiogenesis inhibition).